Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
13.70
-0.15 (-1.08%)
May 21, 2026, 12:14 PM CET

STO:ANNX Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
11.0710.079.598.0112.2910.7
Research & Development
28.0826.2440.8136.0328.3742.13
Other Operating Expenses
-0.25-----
Operating Expenses
38.8936.3150.444.0440.6652.83
Operating Income
-38.89-36.31-50.4-44.04-40.66-52.83
Interest Expense
---0.05--0-1.86
Interest & Investment Income
0.50.470.280.12--
Earnings From Equity Investments
-----0.95
Currency Exchange Gain (Loss)
-1.05-1.05-0.08-0.14-0.071.59
Pretax Income
-39.44-36.89-50.25-44.05-40.73-52.14
Net Income
-39.44-36.89-50.25-44.05-40.73-52.14
Net Income to Common
-39.44-36.89-50.25-44.05-40.73-52.14
Shares Outstanding (Basic)
-75211
Shares Outstanding (Diluted)
-75211
Shares Change (YoY)
-46.31%170.59%14.23%78.30%33.40%
EPS (Basic)
--5.58-11.11-26.36-27.84-63.55
EPS (Diluted)
--5.58-11.11-26.36-27.84-63.55
Free Cash Flow
-39.13-37.05-50.23-43.4-41.17-45.02
Free Cash Flow Per Share
--5.60-11.11-25.97-28.14-54.88
EBITDA
-38.69-36.12-50.2-43.85-40.46-52.63
D&A For EBITDA
0.190.190.190.190.190.19
EBIT
-38.89-36.31-50.4-44.04-40.66-52.83
Source: S&P Global Market Intelligence. Standard template. Financial Sources.